dc.contributor.author |
Mix, M |
en |
dc.contributor.author |
Singh, AK |
en |
dc.contributor.author |
Tills, M |
en |
dc.contributor.author |
Dibaj, S |
en |
dc.contributor.author |
Groman, A |
en |
dc.contributor.author |
Jaggernauth, W |
en |
dc.contributor.author |
Rustum, Y |
en |
dc.contributor.author |
Jameson, Michael |
en |
dc.date.accessioned |
2017-09-07T02:18:56Z |
en |
dc.date.issued |
2015-10 |
en |
dc.identifier.citation |
World Journal of Clinical Oncology 6(5):166-173 Oct 2015 |
en |
dc.identifier.issn |
2218-4333 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/35542 |
en |
dc.description.abstract |
AIM: To investigate whether selenomethionine (SLM) reduces mucositis incidence in patients with head and neck squamous cell cancer (HNSCC) undergoing concurrent chemoradiation (CRT). METHODS: In this multi-institutional, randomized, double-blind phase II trial, patients with Stage III or IV HNSCC received SLM 3600 mug/m(2) or placebo twice daily for 7 d prior to CRT, once daily during CRT, and daily for 3 wk following CRT. CRT consisted of 70 Gy at 2 Gy per fraction with cisplatin 100 mg/m(2) IV on days 1, 22, and 43. RESULTS: Eighteen patients were randomized, 10 received SLM, and there were no differences in baseline factors. There was no difference in mucositis or patient-reported side effects between groups. There was no difference in overall or relapse-free survival at 12 mo. CONCLUSION: Addition of SLM to CRT for HNSCC was well-tolerated but did not lower the incidence of severe mucositis or improve quality of life or survival outcomes |
en |
dc.publisher |
Baishideng Publishing Group Co. Limited |
en |
dc.relation.ispartofseries |
World Journal of Clinical Oncology |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/2218-4333/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
https://creativecommons.org/licenses/by-nc/4.0/ |
en |
dc.title |
Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.5306/wjco.v6.i5.166 |
en |
pubs.issue |
5 |
en |
pubs.begin-page |
166 |
en |
pubs.volume |
6 |
en |
dc.description.version |
VoR - Version of Record |
en |
dc.rights.holder |
Copyright: The authors |
en |
pubs.end-page |
173 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
602892 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Waikato Clinical school |
en |
dc.identifier.eissn |
2218-4333 |
en |
pubs.record-created-at-source-date |
2016-12-19 |
en |